PE/VC  Biomark Capital

     Office Locations:

537 Steamboat Road, Suite 200
Greenwich, CT 06830
Phone: 203-769-2345
Fax: 201-402-1086

Get all office locations for this firm with a National Database subscription or New York Database subscription.


  • Early
  • Late
  • Middle Market



  • Life Sciences & Healthcare
  • Medical Device



    Biomark Capital provides venture funding and assistance to early, mid, and late-stage life science companies. The firm targets companies with novel approaches to diagnostics, therapeutics, medical devices, and digital health that will change the face of healthcare innovation in the future. Biomark Capital's primary investment focus is in North America, along with a specific focus in Russia, Taiwan, India, and China. Initial investments typically range from $5-$10 million dollars.

    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Growth Stage
    (also called Mid-stage)
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B

    Investment Team:

    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription or New York Database subscription.
    Bryant Fong Managing Director
    David Wetherell Managing Partner
    Douglas Lind Managing Director
    Janos Redei Entrepreneur-in-Residence
    Joshua Zelig Director


    Portfolio companies include:


    Recent News: